Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: A review

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 452-463

  Tanaka, Kuniya ^a   Ichikawa, Yasushi ^a   Endo, Itaru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 Stage hepatectomy; Chemotherapy response; Colorectal liver metastases; Effective chemotherapy; Patient survival; Portal vein embolization

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; DRUG RESPONSE; FATTY LIVER; HUMAN; INOPERABLE CANCER; LIVER FIBROSIS; LIVER HEMORRHAGE; LIVER HYPERTROPHY; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT DURATION; TUMOR ABLATION; VEIN RECONSTRUCTION; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIOPERATIVE PERIOD; PORTAL VEIN; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; PERIOPERATIVE CARE; PORTAL VEIN; TREATMENT OUTCOME;

EID: 84862877341     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0291-6     Document Type: Review

References (108)

1. Weiss L, Grundmann E, Torhorst J et al (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195-203 (Pubitemid 17181753)
2. National Comprehensive Cancer Network. (2008) Colon cancer practice guidelines in oncology. Version 2. http://www.nccn.org
3. Borner MM (1999) Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Ann Oncol 10:623-626 (Pubitemid 29342365)
4. Primrose JN (2002) Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut 50:1-5 (Pubitemid 34028291)
5. Wagner JS, Adson MA, Van Heerden JA et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199:502-508 (Pubitemid 14105105)
6. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2:285-288
7. Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2):ii13-ii16 (Pubitemid 36874133)
8. Hugh TJ, Kinsella AR, Poston GJ (1997) Management strategies for colorectal liver metastases-Part II. Surg Oncol 6:31-48 (Pubitemid 27511412)
9. Ekberg H, Tranberg KG, Andersson R et al (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:727-731 (Pubitemid 16011176)
10. Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829-1835
11. Bismuth H, Adam R, Lévi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522 (Pubitemid 26337559)
12. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
13. Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982-999
14. Rees M, Tekkis PP, Welsh FK et al (2008) Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125-135
15. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1064 (Pubitemid 39602132)
16. Gruenberger B, Scheithauer W, Punzengruber R et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120
17. Kornprat P, Jarnagin WR, Gonen M et al (2007) Outcome after hepatectomy formultiple (four ormore) colorectalmetastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151-1160
18. Allen PJ, Kemeny N, Jarnagin W et al (2003) Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109-115
19. Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635-1641
20. Tanaka K, Takakura H, Takeda K et al (2009) Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 250:935-942
21. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30 (Pubitemid 41095110)
22. Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214 (Pubitemid 41079833)
23. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237 (Pubitemid 41095086)
24. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
25. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
26. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208 (Pubitemid 41079832)
27. Ekberg H, Tranberg KG, Andersson R et al (1987) Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11:541-547 (Pubitemid 17131696)
28. Tanaka K, Shimada H, Kubota K et al (2008) Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery 143:259-270
29. Kemeny MM, Adak S, Gray B et al (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 20:1499-1505 (Pubitemid 34260528)
30. Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985 (Pubitemid 34015581)
31. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016 (Pubitemid 351392040)
32. Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669 (Pubitemid 29342371)
33. Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985-992
34. Giacchetti S, Bjarnason GA, Garufi C et al (2004) First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). Proc ASCO 23(Abstr#3526):252
35. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676 (Pubitemid 46797946)
36. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
37. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
38. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal livermetastases: correlation between tumour response and resection rates. Ann Oncol 16:1311-1319 (Pubitemid 41158476)
39. Tanaka K, Shimada H, Kubota K et al (2005) Effectiveness of prehepatectomy intra-arterial chemotherapy for multiple bilobar colorectal cancer metastases to the liver: a clinicopathologic study of peritumoral vasculobiliary invasion. Surgery 137:156-164 (Pubitemid 40174422)
40. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983-4990 (Pubitemid 46631400)
41. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072 (Pubitemid 46622116)
42. Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7 (Pubitemid 43054046)
43. Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118-124
44. Peppercorn PD, Reznek RH, Wilson P et al (1998) Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77:2008-2011 (Pubitemid 28254648)
45. Sørensen P, Edal AL, Madsen EL et al (1995) Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 75:2592-2596
46. Moertel CG, Fleming TR, Macdonald JS et al (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11:2386-2390 (Pubitemid 23353968)
47. Tanaka K, Shimada H, Ueda M et al (2006) Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery 139:599-607
48. Morris-Stiff G, Tan YM, Vauthey JN (2008) Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34:609-614 (Pubitemid 351671976)
49. Pawlik TM, Olino K, Gleisner AL et al (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860-868
50. Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853 (Pubitemid 40744790)
51. DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 22:27-42
52. Kooby DA, Fong Y, Suriawinata A et al (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034-1044 (Pubitemid 37524071)
53. Behrns KE, Tsiotos GG, DeSouza NF et al (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2:292-298 (Pubitemid 128409616)
54. Belghiti J, Hiramatsu K, Benoist S et al (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38-46 (Pubitemid 30439557)
55. Soubrane O, Brouquet A, Zalinski S et al (2010) Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251:454-460
56. Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549-2555
57. Aussilhou B, Dokmak S, Faivre S et al (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553-1559
58. Auer RC, White RR, Kemeny NE et al (2010) Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116:1502-1509
59. Snoeren N, Voest E, van Hillegersberg R (2008) Surgery vs surgery and chemotherapy for colorectal liver metastases. Lancet 372:202-203 author report 203 (Pubitemid 351978099)
60. Welsh FK, Tilney HS, Tekkis PP et al (2007) Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96:1037-1042 (Pubitemid 46608314)
61. Kopetz S, Vauthey JN (2008) Perioperative chemotherapy for resectable hepatic metastases. Lancet 371:963-965 (Pubitemid 351389517)
62. D'Angelica M, Kornprat P, Gonen M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759-765 (Pubitemid 46175324)
63. Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260
64. Zorzi D, Chun YS, Madoff DC et al (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15:2765-2772
65. Hemming AW, Reed AI, Howard RJ et al (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237:686-691
66. Fong Y, Bentrem DJ (2006) CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243:8-9 (Pubitemid 43054047)
67. Shoup M, Gonen M, D'Angelica M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7:325-330 (Pubitemid 36875770)
68. Adam R, Laurent A, Azoulay D et al (2000) Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232:777-785
69. Kianmanesh R, Farges O, Abdalla EK et al (2003) Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 197:164-170 (Pubitemid 36759192)
70. Jaeck D, Oussoultzoglou E, Rosso E et al (2004) A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240:1037-1051 (Pubitemid 39602131)
71. Wicherts DA, Miller R, de Haas RJ et al (2008) Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248:994-1005
72. Farges O, Belghiti J, Kianmanesh R et al (2003) Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237:208-217 (Pubitemid 38173248)
73. Jaeck D, Bachellier P, Nakano H et al (2003) One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg 185:221-229 (Pubitemid 36298887)
74. Kaneko T, Nakao A, Takagi H (2002) Clinical studies of new material for portal vein embolization: comparison of embolic effect with different agents. Hepatogastroenterology 49:472-477 (Pubitemid 34606577)
75. Ko GY, Sung KB, Yoon HK et al (2003) Preoperative portal vein embolization with a new liquid embolic agent. Radiology 227:407-413
76. Tanaka K, Shimada H, Matsuo K et al (2007) Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 33:329-335 (Pubitemid 46488669)
77. Pamecha V, Nedjat-Shokouhi B, Gurusamy K et al (2008) Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolisation and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. Dig Surg 25:387-393
78. Ikeda Y, Matsumata T, Takenaka K et al (1995) Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats. Eur J Surg Oncol 21:188-190
79. Mizutani J, Hiraoka T, Yamashita R et al (1992) Promotion of hepatic metastases by liver resection in the rat. Br J Cancer 65:794-797
80. Harun N, Nikfarjam M, Muralidharan V et al (2007) Liver regeneration stimulates tumor metastases. J Surg Res 138:284-290 (Pubitemid 46365721)
81. Jiang W, Hiscox S, Matsumoto K et al (1999) Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29:209-248 (Pubitemid 29158969)
82. Lukomska B, Dluzniewska J, Polanski J et al (2004) Expression of growth factors in colorectal carcinoma liver metastatic patients after partial hepatectomy: implications for a functional role in cell proliferation during liver regeneration. Comp Hepatol 3(Suppl 1):S52
83. Yoon SS, Kim SH, Gonen M et al (2006) Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 13:353-362 (Pubitemid 43255919)
84. Tanaka K, Shimada H, Matsumoto C et al (2008) Impact of the degree of liver resection on survival for patients with multiple liver metastases from colorectal cancer. World J Surg 32:2057-2069
85. Miyazaki M, Ito H, Nakagawa K et al (1999) Aggressive surgical resection for hepatic metastases involving the inferior vena cava. Am J Surg 177:294-298 (Pubitemid 29218338)
86. Aoki T, Sugawara Y, Imamura H et al (2004) Hepatic resection with reconstruction of the inferior vena cava or hepatic venous confluence for metastatic liver tumor from colorectal cancer. J Am Coll Surg 198:366-372 (Pubitemid 38283727)
87. Tanaka K, Matsuyama R, Takeda K et al (2009) Aggressive liver resection including major-vessel resection for colorectal liver metastases. World J Hepatol 1:79-89
88. Yang Y, Nagano H, Ota H et al (2007) Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141:196-202 (Pubitemid 46149871)
89. Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241-1246
90. Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939-3945 (Pubitemid 46630742)
91. Elias D, Youssef O, Sideris L et al (2004) Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4-9 (Pubitemid 38490093)
92. Dy GK, Krook JE, Green EM et al (2007) Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 25:3469-3474 (Pubitemid 47310885)
93. Cady B, Jenkins RL, Steele GD Jr et al (1998) Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227:566-571 (Pubitemid 28363275)
94. Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722
95. Kokudo N, Miki Y, Sugai S et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137:833-840 (Pubitemid 34743176)
96. Broering DC, Hillert C, Krupski G et al (2002) Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant. J Gastrointest Surg 6:905-913 (Pubitemid 40433478)
97. Altendorf-Hofmann A, Scheele J (2003) A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 12:165-192 xi (Pubitemid 36210866)
98. de Haas RJ, Wicherts DA, Flores E et al (2008) R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248:626-637
99. Tanaka K, Nojiri K, Kumamoto T et al (2011) R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. Eur J Surg Oncol 37:336-343
100. Ng JK, Urbanski SJ, Mangat N et al (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer 112:362-371
101. Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304 (Pubitemid 46323097)
102. Hashimoto T, Minagawa M, Aoki T et al (2008) Caval invasion by liver tumor is limited. J Am Coll Surg 207:383-392
103. Maeba T, Okano K, Mori S et al (2000) Extent of pathologic invasion of the inferior vena cava in resected liver cancer compared with possible caval invasion diagnosed by preoperative images. J Hepatobiliary Pancreat Surg 7:299-305
104. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
105. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338-2344
106. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300 (Pubitemid 46630787)
107. Tangjitgamol S, Manusirivithaya S, Laopaiboon M et al (2009) Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 1:CD006014 Review
108. Mormont MC, Levi F (2003) Cancer chronotherapy: principles, applications, and perspectives. Cancer 97:155-169 (Pubitemid 36033875)